scholarly journals Biochemical Activity and Hypoglycemic Effects ofRumex obtusifoliusL. Seeds Used in Armenian Traditional Medicine

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Anush Aghajanyan ◽  
Armine Nikoyan ◽  
Armen Trchounian
Keyword(s):  
Herbal Remedy ◽  
Density Lipoprotein ◽  
Ethanol Extract ◽  
Liver Glycogen ◽  
Lipoprotein Cholesterol ◽  
Current Therapy ◽  
Total Phenolic ◽  
Control Group ◽  
Biochemical Activity ◽  
Cholesterol Levels

Diabetes mellitus (DM) is a serious chronic metabolic disorder. Various diseases are being treated with medicinal plants and that is because of the less side effects of the current therapy. The diversity of plants in Armenia is due to the singularity of natural environment. However, biochemical activity of these plants has not been studied well. Thus, the goal was to investigate biochemical activity and antihyperglycemic properties ofRumex obtusifoliusL. in rabbits with hyperglycemia. The high content of total phenolic compounds, flavonoids, and tannins has been determined in this plant extract. Oral administration of ethanol extract showed significant effect on hyperglycemia, reducing fasting glucose levels (57.3%, p<0.05), improving glucose tolerance, and increasing liver glycogen content (1.5-fold, p<0.01) compared to the hyperglycemic control group. Furthermore, ethanol extract ofR. obtusifoliusreduced total cholesterol, low-density lipoprotein cholesterol levels, and vice versa increased high-density lipoprotein cholesterol levels and also decreased liver enzymes levels (alanine aminotransferase and aspartate aminotransferase) compared with untreated group. These findings suggest thatR. obtusifoliusmay have beneficial effects and should be supplement, as herbal remedy in the treatment of DM.

Cholesterol Levels In Patients With Newly Diagnosed Chronic Lymphocytic Leukemia: A retrospective Multicenter Study

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 5292-5292
Author(s):  
Irfan Yavasoglu ◽  
Gokhan Pektas ◽  
Fergün Yilmaz ◽  
Gülsüm Akgün ◽  
Anil Tombak ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lymphocytic Leukemia ◽  
Lipoprotein Cholesterol ◽  
Control Group ◽  
Low Density Lipoprotein Cholesterol ◽  
Cholesterol Levels ◽  
Lipid Parameters ◽  
Low Cholesterol ◽  
Retrospective Multicenter Study

Abstract Low cholesterol levels can be detected in solid tumors and hematological malignancies such as muliple myeloma. Moreover chloesterol levels reduced in some experimental studies of patients with chronic lymphocytic leukemia (CLL). In this retrospective multicenter study, lipid levels were retrospectively evaluated in 420 (264 male and 256 female with mean age 64 ± 11 years) patients with newly diagnosed CLL, according to the International CLL study group. 71 (28 male and 43 female with mean age 55 ± 9 years) healthy subjects as control group were included to this study. Lipid parameters such as total cholesterol (TC), high density lipoprotein-cholesterol (HDL-C), very low-density lipoprotein-cholesterol (VLDL-C), and triglyceride levels were measured with enzymatic/ calorimetric method and Architect C800 instrument. Low-density lipoprotein-cholesterol (LDL-C) levels were calculated according to Friedwald formula. Lipid parameters between two groups were compared with Mann-Whitney U test. A value of p< 0.05 was accepted as statistically significant. According to Binet classification, 60% of patients were in stage A, while 25% of them were in stage C. In CLL patients, the levels of TC, HDL-C, and LDL-C were lower than those of control group (p=0.001). There was no significantly difference for triglyceride and VLDL-C levels between two groups (p>0.05) (Table-1). The levels of TC, LDL-C, and HDL-C in the patients with stage C were lower than those of both stage A and stage B (Table-2). Low cholesterol levels in patients with CLL may occur due to increased use of cholesterol by lymphocytes.Table-1Lipid parameters in control group and CLL patientsCLL (N:420)Control (N:71)P valueTC (mg/dl)175±41217±36<0.001HDL-C (mg/dl)37±1153±14<0.001LDL-C (mg/dl)108±30131±29<0.001Triglyceride (mg/dl)140±71147±68>0.05VLDL-C (mg/dl)31±1731±17>0.05Table 2Lipid parameters in the patients according to Binet classificationStage A (n:255)Stage B(n:61)Stage C(n:104)P valueTC(mg/dl)183±38179±43156±40<0.001HDL-C(mg/dl)40±1237±1232±12<0.001LDL-C (mg/dl)112±28110±3398±30<0.001Triglyceride (mg/dl)141±76136±53141±68>0.05VLDL-C(mg/dl)30±1535±3331±13>0.05 Disclosures: Sonmez: Novartis Pharmaceuticals Corporation, Turkey: Membership on an entity’s Board of Directors or advisory committees.

scholarly journals Effect of atorvastatin on spermatogenesis in rats: A stereological study

2021 ◽  
Vol 19 (12) ◽  
pp. 2609-2614
Author(s):  
Ekrem Akdeniz ◽  
Mehmet Emin Onger ◽  
Mustafa Suat Bolat ◽  
Fatih Firat ◽  
Metin Gur ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Study Groups ◽  
Lipoprotein Cholesterol ◽  
Control Group ◽  
Total Testosterone ◽  
Cholesterol Levels ◽  
Significant Difference ◽  
Optical Fractionator ◽  
Rat Spermatogenesis

Purpose: To investigate the effects of oral atorvastatin on spermatogenesis in a rat model.Methods: Rats were equally assigned into control and study groups, the latter receiving atorvastatin (20 mg/kg/day). At the end of 12 weeks, spermatogenetic activity was evaluated using stereological and optical fractionator methods. Serum follicle-stimulating hormone (FSH), total testosterone (TT), and luteinizing hormone (LH) levels were measured using micro–ELISA kits. Total cholesterol, triglyceride (TG), low-density lipoprotein cholesterol (LDL - C), and high-density lipoprotein cholesterol levels were also measured by enzymatic colorimetric assays.Results: Testicular stereological analysis revealed that atorvastatin reduced Sertoli cell numbers (p < 0.001), spermatogonia (p < 0.001), spermatocytes (p < 0.001), and seminiferous tubule diameters (p < 0.001). LDL – C (p = 0.01) and TG (p = 0.01) values were significantly lower in the study group compared with the control group. There was no significant difference in FSH (p = 0.44), LH (p = 0.48),and TT (p = 0.06) levels between the groups.Conclusion: The findings show that atorvastatin causes deleterious effects on rat spermatogenesis. It should therefore be used with caution in clinical practice owing to its potential adverse effects, especially on male fertility. Keywords: Statin, Atorvastatin, Spermatogenesis, Stereology, Testis

Effect of dietary probiotic, antibiotic or combination on broiler performance, cecum microbial population and ileal development

2020 ◽  
Vol 21 (3) ◽  
pp. 74-79
Author(s):  
Ahmed Elbaz ◽  
Said El-sheikh
Keyword(s):  
Control Diet ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Experimental Period ◽  
Nutrient Digestibility ◽  
Lipoprotein Cholesterol ◽  
Control Group ◽  
Gut Health ◽  
Feed Conversion ◽  
Broiler Performance

Objective: To investigate the effect of antibiotics and/or probiotics on broiler performance, some serum metabolites, cecum microflora composition, and ileum histomorphology under the Egyptian conditions. Design: Randomized controlled experimental study. Animals: Two hundred forty 1-day-old Ross (308) chicks were reared till 35 days of age. Procedures: The birds were randomly allocated into four main groups: a control diet without additives (CON); probiotic (Lactobacillus acidophilus) supplemented diet (PRO); antibiotic (Avilamycin) supplemented diet (ANT) and a mix group (AP) that received antibiotic in the diet form 1 to 4 days of age and treated during the rest of the experimental period with probiotics. Results: Chickens fed on probiotic or antibiotic diets had linear improvement in live body weight (LBW) and feed conversion ratio (FCR) compared with the control group, while the best LBW and FCR were in the AP group. An improvement in the nutrient digestibility was observed in the probiotic added groups (PRO and AP). Serum cholesterol and low-density lipoprotein cholesterol contents decreased when antimicrobial (probiotic or antibiotic) supplementations were used, while there was an increase in high-density lipoprotein cholesterol contents, serum total protein, and albumin levels. Among all groups, cecum Clostridium perfringens and Escherichia coli counts decreased; however, there was an increase in Lactobacillus count compared to the control group. In probiotic supplemented groups (PRO and AP), a significant (P<0.05) improvement in ilea architecture. Conclusion and clinical relevance: Using probiotic after initial treatment with an antibiotic in broiler diets had a positive effect on broiler growth performance, gut health (improved cecum microbial populations and ileum histomorphology), and nutrient digestibility.

Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?

2021 ◽  
pp. 107424842110236
Author(s):  
Ruihai Zhou ◽  
George A. Stouffer ◽  
Sidney C. Smith
Keyword(s):  
Cardiovascular Disease ◽  
Clinical Outcomes ◽  
Mechanism Of Action ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Blood Cholesterol ◽  
Atherosclerotic Cardiovascular Disease ◽  
Pcsk9 Inhibitors ◽  
Cholesterol Lowering ◽  
Cholesterol Levels

Hypercholesterolemia is a well-established risk factor for atherosclerotic cardiovascular disease (ASCVD). Low-density lipoprotein cholesterol (LDL-C) has been labeled as “bad” cholesterol and high-density lipoprotein cholesterol (HDL-C) as “good” cholesterol. The prevailing hypothesis is that lowering blood cholesterol levels, especially LDL-C, reduces vascular deposition and retention of cholesterol or apolipoprotein B (apoB)-containing lipoproteins which are atherogenic. We review herein the clinical trial data on different pharmacological approaches to lowering blood cholesterol and propose that the mechanism of action of cholesterol lowering, as well as the amplitude of cholesterol reduction, are critically important in leading to improved clinical outcomes in ASCVD. The effects of bile acid sequestrants, fibrates, niacin, cholesteryl ester transfer protein (CETP) inhibitors, apolipoprotein A-I and HDL mimetics, apoB regulators, acyl coenzyme A: cholesterol acyltransferase (ACAT) inhibitors, cholesterol absorption inhibitors, statins, and proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors, among other strategies are reviewed. Clinical evidence supports that different classes of cholesterol lowering or lipoprotein regulating approaches yielded variable effects on ASCVD outcomes, especially in cardiovascular and all-cause mortality. Statins are the most widely used cholesterol lowering agents and have the best proven cardiovascular event and survival benefits. Manipulating cholesterol levels by specific targeting of apoproteins or lipoproteins has not yielded clinical benefit. Understanding why lowering LDL-C by different approaches varies in clinical outcomes of ASCVD, especially in survival benefit, may shed further light on our evolving understanding of how cholesterol and its carrier lipoproteins are involved in ASCVD and aid in developing effective pharmacological strategies to improve the clinical outcomes of ASCVD.

Sign in / Sign up

Export Citation Format

Share Document